Micro-Flow Imaging (MFI) Applications

The detection of subvisible particles is a critical step in biotherapeutic development to determine the safety of a biotherapeutic. Micro-Flow Imaging (MFI) detects different types of particles, from glass shards to protein aggregates as small as 1 µm. MFI is used for particle analysis in formulation development of different biotherapeutics.

Formulation Development | Quality Control | Gene Therapy | Biosimilar Development

Formulation Development

MFI systems enable the detection of translucent sub-visible particles that are 1 – 300 µm in size. Analyze up to 90 samples/run and up to 150 µL/minute at 900,000 particles/mL.

MFI particle classifications: Inherent, Intrinsic, Extrinsic

MFI particle classifications based on conventions formalized by Pharmacopeial agencies. These morphological measurements help pharmaceutical companies and regulators assess the quality and safety of biopharmaceutical products.

Quality Control

Get the size, count, and shape of subvisible particles, and easily distinguish between proteinaceous and other particles, like aggregates and silicon oil droplets.

MFI Differentiation Protein Aggregates

Differentiation of Protein Aggregates from Non-Aggregates. The MFI 5000 Series gives you the size, concentration and image for each particle in just one test and then lets you isolate them by different sub-populations.

Gene Therapy

Assess the stability of your AAVs under various stress conditions. Identify aggregates and impurities in your samples with higher sensitivity on MFI Instruments than light obscuration methods.

Stability assessment ensuring AAV vector particles maintain their structural and functional integrity over time

Stability assessment plays a pivotal role in ensuring AAV vector particles maintain their structural and functional integrity over time, minimizing impacts on potency, safety, and efficacy. Typical methods of AAV stability analysis, such as dynamic light scattering (DLS) and size exclusion chromatography (SEC) are limited by resolution and offer varying degrees of quantification.

By moving to a direct detection method, you can get higher levels of sensitivity in less time, providing robust stability data to simplify regulatory approvals.

Biosimilar Development

Get sensitive and reproducible detection of aggregates and other particle contaminants in biosimilars. MFI gives you valuable and early indicators of stability during formulation, development, and manufacturing.

Real time particle formation of trastuzumab

Particle formation of trastuzumab innovator and biosimilar during real time, accelerated, and stress tests. Shown are mean values with error bars representing the standard deviations of two replicates.